Fortis C-DOC Centre of Excellence for Diabetes, Metabolic Diseases, and Endocrinology, New Delhi, India; National Diabetes, Obesity, and Cholesterol Foundation, New Delhi, India; Diabetes Foundation (India), New Delhi, India.
Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
Lancet Diabetes Endocrinol. 2018 Dec;6(12):979-991. doi: 10.1016/S2213-8587(18)30199-2. Epub 2018 Oct 1.
Compared with other ethnic groups, south Asian people with type 2 diabetes tend to develop the disease at a younger age and manifest with higher glycaemia, dyslipidaemia, nephropathy, and cardiovascular diseases. Additionally, specific issues that can affect treatment of type 2 diabetes in south Asia include poor awareness of the disease, delay in diagnosis, inadequate treatment, the use of ineffective and often harmful alternative medicines, and frequent non-compliance with lifestyle recommendations and drug treatment. Disease development at younger ages, delayed diagnosis, and inadequate management result in early development of severe complications and premature mortality. In this Series paper, we describe the challenges associated with the increasing burden of type 2 diabetes in south Asia and discuss ways to improve clinical care of people with the disorder in the region (defined to include Bangladesh, Bhutan, India, Nepal, Pakistan, and Sri Lanka). Treatment of diabetes in south Asia needs to be individualised on the basis of diverse and heterogeneous lifestyle, phenotype, environmental, social, cultural, and economic factors. Aggressive management of risk factors from diagnosis is necessary to reduce the risk of microvascular and macrovascular complications, focusing on provision of basic treatments (eg, metformin, low-cost statins, and blood pressure-lowering drugs) and other interventions such as smoking cessation. Strengthening of the primary care model of care, better referral linkages, and implementation of rehabilitation services to care for patients with chronic complications will be important. Finally, improvement of physicians' skills, provision of relevant training to non-physician health-care workers, and the development and regular updating of national clinical management guidelines will also be crucial to improve diabetes care in the region.
与其他族裔群体相比,南亚 2 型糖尿病患者发病年龄更早,血糖、血脂、肾病和心血管疾病等并发症更为严重。此外,影响南亚 2 型糖尿病治疗的一些特殊问题包括:对疾病的认识不足、诊断延迟、治疗不充分、使用无效且往往有害的替代药物、以及经常不遵守生活方式建议和药物治疗。发病年龄较早、诊断延迟和管理不充分导致严重并发症和过早死亡的发生更早。在本系列论文中,我们描述了南亚 2 型糖尿病负担日益加重所面临的挑战,并讨论了改善该地区(包括孟加拉国、不丹、印度、尼泊尔、巴基斯坦和斯里兰卡) 2 型糖尿病患者临床护理的方法。南亚 2 型糖尿病的治疗需要根据多样化和异质的生活方式、表型、环境、社会、文化和经济因素进行个体化。从诊断开始就需要积极管理风险因素,以降低微血管和大血管并发症的风险,重点是提供基本治疗(如二甲双胍、低成本他汀类药物和降压药物)和其他干预措施,如戒烟。加强基层医疗保健模式、更好的转诊联系以及实施康复服务以照顾慢性并发症患者将是非常重要的。最后,提高医生的技能、为非医师卫生保健工作者提供相关培训以及制定和定期更新国家临床管理指南对于改善该地区的糖尿病护理也至关重要。